Biotechnology

Enzymatic DNA Synthesis Market Growth Scope 2022 – Growing Demand for Personalized Medicine

Enzymatic DNA synthesis is a well-established technique of DNA synthesis that is useful in synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and other advanced biological techniques. It is also very helpful to maintain the DNA library and custom DNA synthesis. Major factors driving the market growth include the rising prevalence of genetic disorders and the surging number of product launches. Additionally, growing demand for personalized medicine and DNA data storage is likely to emerge as a significant future trend in the market during the forecast period.

 

Twist Bioscience Corporation and Genscript – Notable Market Players in the Enzymatic DNA Synthesis Market

 

The enzymatic DNA synthesis market is comprised of top players involving Telesis Bio Inc; Evonetix; Ansa Biotechnologies, Inc.; Camena Bio; GenScript Biotech Corp.; Molecular Assemblies; DNA Script; Touchlight; Synbio Technologies; and Twist Bioscience; and others. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the market players have also deployed several utilized inorganic strategies, including mergers & acquisitions, partnerships, and collaborations.

Below are the major growth strategies undertaken by the players operating in the global enzymatic DNA synthesis market:

Year

News

Oct-2022 Codex DNA, Inc., announced a plan to change its Company name to Telesis Bio.
The innovative and pioneering spirit, versatility, and power of the Company’s technologies
have enabled them to expand its portfolio to include an array of tools for both synthetic
biology and genomics applications, and to reflect the expansion, an initiative to a
change name to Telesis Bio was taken.
Jul-2022 Touchlight entered into a non-exclusive patent license agreement with Pfizer.
Under the license agreement, Pfizer has rights to Touchlight’s enzymatic dbDNA
patent portfolio for worldwide use in Pfizer’s manufacture and commercialization
of its mRNA-based vaccines, therapeutics, and gene therapies. The agreement
includes an upfront payment, clinical and commercial milestone payments, and
royalties to Touchlight upon commercialization.
Apr-2022 Molecular Assemblies, Inc. and Codexis, Inc. announced an update
on their partnership to engineer enzymes to deliver differentiated solutions
for the enzymatic synthesis of DNA. A highly evolved DNA polymerase
(of Codexis) is used to develop a high-performing enzyme to enable
Molecular Assemblies’ Fully Enzymatic Synthesis (FES) and access to
Key Customer Program.
Nov-2021 DNA Script obtained the CE marking for its SYNTAX System,
the first EDS-powered benchtop DNA printer. With the marking,
the SYNTAX System meets EU safety, health, and environmental
protection guidelines, and the Company can begin commercial sales
of the SYNTAX System in European countries.

Leave a Reply

Your email address will not be published.